Physician profile
Sharon Adams
NPI 1821324278
$10,257.04
in general payments reported to CMS, 2019-2025
28 companies · $2,542 in 2025
The $2,542 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,896 · 2022: $1,864 · 2023: $1,671 · 2024: $2,283 · 2025: $2,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,288 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,288.33 |
| Education | $208.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,573.93 | 2021-2025 | Linzess, Creon, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,398.65 | 2021-2025 | Xifaxan, Plenvu, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,075.92 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,033.49 | 2021-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $651.16 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $527.98 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $504.69 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $483.38 | 2022-2025 | |
| Ardelyx, INC. | $308.62 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $293.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $259.53 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $209.32 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $208.77 | 2024-2025 | Omvoh |
| Pfizer INC. | $165.18 | 2021-2025 | |
| Evoke Pharma, INC. | $110.10 | 2021-2023 | Gimoti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $57.00 | 2023 | Hulio |
| Braintree Laboratories, INC. | $56.91 | 2021-2025 | Suflave |
| Gilead Sciences, INC. | $53.90 | 2021-2023 | Epclusa |
| Novo Nordisk INC | $46.76 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.80 | 2023-2024 | Cyltezo |
| Celgene Corporation | $43.75 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $29.63 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $27.73 | 2023 | Idacio |
| Medtronic, INC. | $22.61 | 2024 | Gi Genius |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Ferring Pharmaceuticals INC. | $19.13 | 2024 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $16.58 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $14.63 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.